PepGen Announces Executive Team Promotions
11 June 2024 - 9:00PM
Business Wire
Michelle Mellion, M.D., promoted to Chief
Medical Officer
Hayley Parker, Ph.D., promoted to Senior Vice
President, Global Regulatory Affairs
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology
company advancing the next generation of oligonucleotide therapies
with the goal of transforming the treatment of severe neuromuscular
and neurological diseases, today announced two executive team
promotions effective immediately: Michelle Mellion, M.D., to Chief
Medical Officer and Hayley Parker, Ph.D., to Senior Vice President,
Global Regulatory Affairs.
“I am excited to announce the well-deserved promotions of
Michelle and Hayley, a true testament to their hard work,
dedication, and leadership. Since joining PepGen, they have played
integral roles in driving both our clinical and regulatory
strategies, advancing our pipeline of differentiated
oligonucleotides, and paving a path for future commercialization,”
said James McArthur, Ph.D., President and CEO of PepGen. “As we
continue to execute on our goals and prepare for preliminary data
readouts and additional trial initiations, I look forward to
working with our incredible team to take the vital next steps in
bringing our potentially disease-modifying therapies to people
living with rare muscle disorders."
Michelle Mellion, M.D., promoted to Chief Medical
Officer, joined PepGen as Senior Vice President, Head of Clinical
Development and has been instrumental in overseeing the Company’s
global clinical development strategy, as well as advancing the
Company’s neuromuscular programs into the clinic. She was also
recently appointed to Medical Advisor of the FSHD Society.
Previously, Dr. Mellion served in roles of increasing
responsibility at Fulcrum Therapeutics, where she led the design
and implementation of Phase I/II/III clinical trials for the
company’s novel treatment of facioscapulohumeral muscular
dystrophy. In parallel, she worked as an Attending Physician
affiliated with Tufts Medical Center, specializing in Neurology as
a member of their Pediatrics department. Earlier, Dr. Mellion held
leadership roles at Vertex Pharmaceuticals and Biogen, as well as
working as an Attending Neurologist in the Muscular Dystrophy
Association (MDA) clinic and Attending Physician and Assistant
Professor of Neurology at Alpert Medical School, Brown University.
She completed her residency at Brown Medical School, received her
M.D. from the Wake Forest University School of Medicine, and earned
her B.A. in Molecular Biology from Colgate University.
Hayley Parker, Ph.D., promoted to Senior Vice President,
Global Regulatory Affairs, joined PepGen as Vice President,
Regulatory Affairs and has been pivotal in developing and executing
the Company’s global regulatory strategy and in interacting with
regulatory authorities. Previously, she served as Vice President,
Regulatory Affairs at Scholar Rock, accountable for the global
regulatory strategy for their lead neuromuscular program. Earlier,
Dr. Parker gained experience in rare disease holding various
leadership positions at Vertex Pharmaceuticals where, as part of
the Regulatory Leadership team, she was Head of Global Labelling
and global therapeutic strategic lead for early phase pain assets,
and at Biogen working in rare diseases with high unmet medical
need, such as Spinal Muscular Atrophy. She earned her Ph.D. in
Molecular Biology and Respiratory Medicine at Imperial College,
London, and her B.Sc. in Molecular Biology from the University of
Hertfordshire.
About PepGen
PepGen Inc. is a clinical-stage biotechnology company advancing
the next-generation of oligonucleotide therapies with the goal of
transforming the treatment of severe neuromuscular and neurological
diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO,
platform is founded on over a decade of research and development
and leverages cell-penetrating peptides to improve the uptake and
activity of conjugated oligonucleotide therapeutics. Using these
EDO peptides, we are generating a pipeline of oligonucleotide
therapeutic candidates that are designed to target the root cause
of serious diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240611396164/en/
Investor Contact Noel
Donnelly Chief Financial Officer ndonnelly@pepgen.com
Media Contact Julia Deutsch
Lyra Strategic Advisory Jdeutsch@lyraadvisory.com
PepGen (NASDAQ:PEPG)
Historical Stock Chart
From Nov 2024 to Dec 2024
PepGen (NASDAQ:PEPG)
Historical Stock Chart
From Dec 2023 to Dec 2024